News

July 28, 2020

ReAlta Life Sciences Announces U.S. FDA Clearance of First Investigational New Drug Application for RLS-0071

Phase 1 Trial for the Treatment of Patients with Acute Lung Injury Due to COVID 19 Anticipated to Begin in Third Quarter of 2020 Norfolk, VA, […]
June 29, 2020

ReAlta Life Sciences to Participate in Oppenheimer’s Private Life Sciences Company Call Series

Norfolk, VA, June 29, 2020 – ReAlta Life Sciences, Inc. announced today that Dr. Ulrich Thienel, MD, PhD, Chief Executive Officer, is scheduled to participate in […]
June 19, 2020

ReAlta Life Sciences To Receive a Commonwealth Research Commercialization Fund (CRCF) Grant

ReAlta Life Sciences is pleased to have received a Commonwealth Research Commercialization Fund (CRCF) grant. This award will help support the clinical development of ReAlta’s lead […]
May 28, 2020

ReAlta Life Sciences, Inc. to participate in the Virtual 2020 BIO International Convention, BIO Digital

Norfolk, VA, May 28, 2020 — ReAlta Life Sciences, Inc. announced today that it will participate in the upcoming virtual BIO International Convention, BIO Digital, being held June 8 – 12, […]
April 21, 2020

ReAlta Life Sciences Closes $14 Million Series A2 Financing to Support Transition into a Clinical Organization

Proceeds to Fund Advancement of Programs Addressing Acute Lung Injury Due to COVID-19 and Severe Birth Asphyxia (HIE) Norfolk, VA, April 21, 2020 — ReAlta Life […]
April 9, 2020

ReAlta Life Sciences Strengthens Board of Directors with Election of Edward Heidt as Chair and Appointments of Dr. Jonathan Zalevsky and Christine Neikirk

Norfolk, VA, April 9, 2020 — ReAlta Life Sciences, Inc., a biotech company dedicated to harnessing the power of the immune system through its PIC1 technology […]
March 10, 2020

ReAlta Life Sciences Strengthens Board of Directors with Appointments of Industry Leaders Dr. Deborah Geraghty and Dr. Azmi Nabulsi

Norfolk, VA, March 10, 2020 — ReAlta Life Sciences, Inc., a biotechnology company dedicated to harnessing the power of the immune system to address life-threatening medical […]
February 6, 2020

ReAlta Life Sciences Announces FDA Orphan Drug Designation for PIC1 for the Treatment of Hypoxic-Ischemic Encephalopathy

PIC1 positioned as a novel pharmacological intervention to improve survival and cognitive outcomes for newborns affected by devastating disease Norfolk, VA, February 6, 2020 — ReAlta […]
January 2, 2020

EVMS scientist and CHKD pediatrician pursue drug for potential “blue baby” treatment

THE VIRGINIAN-PILOT | DEC 29, 2019 https://www.pilotonline.com/news/health/vp-nw-fzx19-realta-life-sciences-20191229-ufzi7vhgu5f3nppfatihjcgq3a-story.html
November 6, 2019

ReAlta Life Sciences, Inc. to participate in 3rd Annual Complement-based Drug Development Summit 2019 in Boston, Massachusetts

Norfolk, VA, November 6, 2019 — ReAlta Life Sciences, Inc. announced today that it will participate in the upcoming Complement-based Drug Development Summit being held November 13-15, 2019 in Boston, […]
Loading...